Structural studies of antitumor compounds that target the RING domain of MDM2
- PMID: 35900024
- PMCID: PMC9301682
- DOI: 10.1002/pro.4367
Structural studies of antitumor compounds that target the RING domain of MDM2
Retraction in
-
Retraction.Protein Sci. 2023 Jun;32(6):e4657. doi: 10.1002/pro.4657. Protein Sci. 2023. PMID: 37249231 Free PMC article. No abstract available.
Abstract
Mouse double minute 2 homolog (MDM2) is an E3 ubiquitin-protein ligase that is involved in the transfer of ubiquitin to p53 and other protein substrates. The expression of MDM2 is elevated in cancer cells and inhibitors of MDM2 showed potent anticancer activities. Many inhibitors target the p53 binding domain of MDM2. However, inhibitors such as Inulanolide A and MA242 are found to bind the RING domain of MDM2 to block ubiquitin transfer. In this report, crystal structures of MDM2 RING domain in complex with Inulanolide A and MA242 were solved. These inhibitors primarily bind in a hydrophobic site centered at the sidechain of Tyr489 at the C-terminus of MDM2 RING domain. The C-terminus of MDM2 RING domain, especially residue Tyr489, is required for ubiquitin discharge induced by MDM2. The binding of these inhibitors at Tyr489 may interrupt interactions between the MDM2 RING domain and the E2-Ubiquitin complex to inhibit ubiquitin transfer, regardless of what the substrate is. Our results suggest a new mechanism of inhibition of MDM2 E3 activity for a broad spectrum of substrates.
Keywords: E3 ubiquitin ligase; RING finger protein; crystal structure; drug design; inhibition mechanism.
© 2022 The Protein Society.
Conflict of interest statement
The authors declare no conflict of interest with this publication.
Figures




Similar articles
-
The Mdm2 RING domain C-terminus is required for supramolecular assembly and ubiquitin ligase activity.EMBO J. 2007 Jan 10;26(1):90-101. doi: 10.1038/sj.emboj.7601465. Epub 2006 Dec 14. EMBO J. 2007. PMID: 17170710 Free PMC article.
-
Targeting RING domains of Mdm2-MdmX E3 complex activates apoptotic arm of the p53 pathway in leukemia/lymphoma cells.Cell Death Dis. 2015 Dec 31;6(12):e2035. doi: 10.1038/cddis.2015.358. Cell Death Dis. 2015. PMID: 26720344 Free PMC article.
-
Autoactivation of the MDM2 E3 ligase by intramolecular interaction.Mol Cell Biol. 2014 Aug;34(15):2800-10. doi: 10.1128/MCB.00246-14. Epub 2014 May 19. Mol Cell Biol. 2014. PMID: 24842904 Free PMC article.
-
p53 regulation: teamwork between RING domains of Mdm2 and MdmX.Cell Cycle. 2011 Dec 15;10(24):4225-9. doi: 10.4161/cc.10.24.18662. Epub 2011 Dec 15. Cell Cycle. 2011. PMID: 22134240 Review.
-
Mdm2 and MdmX partner to regulate p53.FEBS Lett. 2012 May 21;586(10):1390-6. doi: 10.1016/j.febslet.2012.02.049. Epub 2012 Mar 8. FEBS Lett. 2012. PMID: 22673503 Review.
Cited by
-
Targeting the MYCN-MDM2 pathways for cancer therapy: Are they druggable?Genes Dis. 2023 Oct 27;12(2):101156. doi: 10.1016/j.gendis.2023.101156. eCollection 2025 Mar. Genes Dis. 2023. PMID: 39802403 Free PMC article. Review.
References
-
- Hussain SP, Schwank J, Staib F, Wang XW, Harris CC. TP53 mutations and hepatocellular carcinoma: Insights into the etiology and pathogenesis of liver cancer. Oncogene. 2007;26:2166–2176. PMID: 17401425 {Medline}, 2176. - PubMed
-
- Staib F, Hussain SP, Hofseth LJ, Wang XW, Harris CC. TP53 and liver carcinogenesis. Hum Mutat. 2003;21:201–216. PMID: 12619106 {Medline}. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous